SAN FRANCISCO (GenomeWeb) – Natera plans to focus on three main goals in the coming year, according to its new CEO, Steve Chapman: expanding its leadership in reproductive health by pushing toward becoming cash-flow break-even in that business, establishing Signatera as a standard test in cancer care, and commercializing and securing reimbursement coverage for its kidney transplantation test.
Menu
Home › Business, Policy & Funding › Business News › New Natera CEO Highlights Three Goals for Company at JP Morgan
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.
By MilliporeSigma
By MilliporeSigma
By MilliporeSigma
Mar
18
Featured Webinar
Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind
Sponsored by
Thermo Fisher Scientific
Mar
29
Featured Webinar
Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs
Sponsored by
Thermo Fisher Scientific
Mar
31
Sponsored by
MilliporeSigma
What's Popular?
In Molecular Diagnostics
Sponsorships
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.